Nektar Therapeutics宣布公开募股2.5亿美元

2026-04-21 04:11

Nektar Therapeutics (NKTR) announced on Monday that it has commenced an underwritten public offering of $250M of its shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
All the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar.
In addition, Nektar intends to grant the underwriters a 30-day option to purchase up to an additional $37.5M of shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development (including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.
Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering.
NKTR -0.05% after hours to $100.48.
Source: Press Release

More on Nektar Therapeutics